Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases

JIANG Shasha; WANG Chen; LU Ran; LIU Fengjun; LI Jun; WANG Bin

doi:10.12211/2096-8280.2023-071

您当前的位置：

首页 >

文章列表页 >

Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases

Invited Review | 更新时间：2025-03-20

- Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases
- Synthetic Biology Journal Vol. 5, Issue 2, Pages: 294-309(2024)
- 作者机构：
  
  1.青岛大学基础医学院，病原生物学系，山东青岛 266000
  2.北京市朝阳区疾病预防控制中心，微生物检验科，北京 100021
  3.青岛大学基础医学院，特种医学系，山东青岛 266000
- 作者简介：
- 基金信息：
- DOI：10.12211/2096-8280.2023-071
  CLC： Q819
- Received：07 October 2023，
  
  Revised：2024-03-12，
  
  Published：30 April 2024
- 稿件说明：
移动端阅览
江莎莎，王晨，路冉，刘俸君，李俊，王斌. T细胞免疫反应载体疫苗在人类疾病预防和治疗中的应用［J］. 合成生物学， 2024， 5（2）： 294-309

JIANG Shasha， WANG Chen， LU Ran， LIU Fengjun， LI Jun， WANG Bin. Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases［J］. Synthetic Biology Journal， 2024， 5（2）： 294-309
江莎莎，王晨，路冉，刘俸君，李俊，王斌. T细胞免疫反应载体疫苗在人类疾病预防和治疗中的应用［J］. 合成生物学， 2024， 5（2）： 294-309 DOI： 10.12211/2096-8280.2023-071.

JIANG Shasha， WANG Chen， LU Ran， LIU Fengjun， LI Jun， WANG Bin. Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases［J］. Synthetic Biology Journal， 2024， 5（2）： 294-309 DOI： 10.12211/2096-8280.2023-071.

摘要

人类疾病，特别是传染病和癌症，对公共卫生安全和全球经济构成前所未有的挑战。预防和治疗性疫苗的开发是应对人类疾病的优先对策。本文综述了疫苗载体的免疫学原理、T细胞载体疫苗设计策略及疫苗研究进展，为新型疫苗的设计提供新的思路。T细胞可以在机体发生感染后分化成不同的效应T细胞群，它们可以起到清除病原体的作用，关于效应T细胞功能和机制的研究对于设计能够引发基于T细胞免疫的疫苗至关重要。目前很多病毒（例如HIV、HCMV感染）和肿瘤疫苗的研发都侧重于T细胞类疫苗，在所有疫苗种类中，激活T细胞免疫反应的载体疫苗具有显著优势。许多来源的载体，包括病毒载体、细菌载体和核酸载体，它们在抗原提呈能力、免疫原性和保护效力方面都有良好的表现。此外，还总结了T细胞载体疫苗设计的策略，包括确定适当的抗原提呈途径和载体递送途径、确保生物安全性、如何选择合适的疫苗的载体、各种载体疫苗的优缺点等，尤其是mRNA疫苗在应对新冠疫情中发挥了重要的作用。疫苗载体的技术进步将会加速新型疫苗的研发，并且能促进人们对突发公共卫生事件的应对。

Abstract

Human diseases

especially infectious diseases and cancers

pose unprecedented challenges to public health and the global economy

making the development of preventive and therapeutic vaccines a top priority for addressing these challenges. Among all vaccines

vector vaccines that activate T cell immune responses have significant advantages. This article reviews the immunological principles of vector vaccines

strategies for designing T cell vector vaccines

and their research advances. T cells

upon infection

can differentiate into various effector T cell subsets that play a crucial role in clearing pathogens. Research on the functions and mechanisms of effector T cells is essential for designing vaccines that can elicit T cell-mediated immunity. Currently

the development of vaccines for many viruses such as HIV and HCMV as well as cancers focuses on T cell-based vaccines. Various vectors

including viral vectors

bacterial vectors

and nucleic acid vectors

exhibit excellent performance on antigen delivery capability

immunogenicity

and protective efficacy. In addition

this article summarizes strategies for designing T-cell vector vaccines

including identifying appropriate antigen presentation pathways and vector delivery routes

ensuring biological safety

selecting suitable vaccine vectors

and evaluating the advantages and disadvantages of various vector vaccines. Notably

mRNA vaccines have played a crucial role in addressing the challenges posed by the COVID-19 pandemic. Technological advancements in vector vaccines are expected to accelerate the development of novel vaccines and enhance preparedness for emerging public health events. This review provides insights for the design of vector vaccines that are both safe and efficient. With advancements in vector vaccine technology and the progress of various interdisciplinary approaches

the next generation of vaccine development will continue to drive the evolution of vaccinology.

关键词

Keywords

references

CROTTY S . Follicular helper CD4 T cells (TFH) [J ] . Annual Review of Immunology , 2011 , 29 : 621 - 663 .

ZHU J F , YAMANE H , PAUL W E . Differentiation of effector CD4 T cell populations* [J ] . Annual Review of Immunology , 2010 , 28 : 445 - 489 .

SALLUSTO F , LANZAVECCHIA A , ARAKI K , et al . From vaccines to memory and back [J ] . Immunity , 2010 , 33 ( 4 ): 451 - 463 .

LEVIN M J , OXMAN M N , ZHANG J H , et al . Varicella - zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine [J ] . The Journal of Infectious Diseases , 2008 , 197 ( 6 ): 825 - 835 .

MCELHANEY J E , XIE D X , HAGER W D , et al . T cell responses are better correlates of vaccine protection in the elderly [J ] . Journal of Immunology , 2006 , 176 ( 10 ): 6333 - 6339 .

PANTALEO G , KOUP R A . Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know [J ] . Nature Medicine , 2004 , 10 ( 8 ): 806 - 810 .

BUNDE T , KIRCHNER A , HOFFMEISTER B , et al . Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells [J ] . The Journal of Experimental Medicine , 2005 , 201 ( 7 ): 1031 - 1036 .

HOFT D F . Tuberculosis vaccine development: goals, immunological design, and evaluation [J ] . Lancet , 2008 , 372 ( 9633 ): 164 - 175 .

REYES-SANDOVAL A , PEARSON F E , TODRYK S , et al . Potency assays for novel T-cell-inducing vaccines against malaria [J ] . Current Opinion in Molecular Therapeutics , 2009 , 11 ( 1 ): 72 - 80 .

REINA-CAMPOS M , SCHARPING N E , GOLDRATH A W . CD8 + T cell metabolism in infection and cancer [J ] . Nature Reviews Immunology , 2021 , 21 ( 11 ): 718 - 738 .

CHAPMAN N M , BOOTHBY M R , CHI H B . Metabolic coordination of T cell quiescence and activation [J ] . Nature Reviews Immunology , 2020 , 20 ( 1 ): 55 - 70 .

SADELAIN M , RIVIÈRE I , RIDDELL S . Therapeutic T cell engineering [J ] . Nature , 2017 , 545 ( 7655 ): 423 - 431 .

SUN L N , SU Y H , JIAO A J , et al . T cells in health and disease [J ] . Signal Transduction and Targeted Therapy , 2023 , 8 ( 1 ): 235 .

KUMAR B V , CONNORS T J , FARBER D L . Human T cell development, localization, and function throughout life [J ] . Immunity , 2018 , 48 ( 2 ): 202 - 213 .

CHEN L P , FLIES D B . Molecular mechanisms of T cell co-stimulation and co-inhibition [J ] . Nature Reviews Immunology , 2013 , 13 ( 4 ): 227 - 242 .

HENRY C J , ORNELLES D A , MITCHELL L M , et al . IL-12 produced by dendritic cells augments CD 8 + T cell activation through the production of the chemokines CCL1 and CCL17 [J ] . Journal of Immunology , 2008 , 181 ( 12 ): 8576 - 8584 .

DÍAZ-MONTERO C M , EL NAGGAR S , AL KHAMI A , et al . Priming of naive CD8 + T cells in the presence of IL-12 selectively enhances the survival of CD8 + CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model [J ] . Cancer Immunology, Immunotherapy , 2008 , 57 ( 4 ): 563 - 572 .

RAMOS H J , DAVIS A M , COLE A G , et al . Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8 + effector versus central memory T-cell fates [J ] . Blood , 2009 , 113 ( 22 ): 5516 - 5525 .

REDEKER A , WELTEN S P , BAERT M R , et al . The quantity of autocrine IL-2 governs the expansion potential of CD8 + T cells [J ] . Journal of Immunology , 2015 , 195 ( 10 ): 4792 - 4801 .

GETT A V , HODGKIN P D . A cellular calculus for signal integration by T cells [J ] . Nature Immunology , 2000 , 1 ( 3 ): 239 - 244 .

BORST J , AHRENDS T , BĄBAŁA N , et al . CD4 + T cell help in cancer immunology and immunotherapy [J ] . Nature Reviews Immunology , 2018 , 18 ( 10 ): 635 - 647 .

RUTERBUSCH M , PRUNER K B , SHEHATA L , et al . In vivo CD4 + T cell differentiation and function: revisiting the Th1/Th2 paradigm [J ] . Annual Review of Immunology , 2020 , 38 : 705 - 725 .

MARTIN M D , BADOVINAC V P , GRIFFITH T S . CD4 T cell responses and the sepsis-induced immunoparalysis state [J ] . Frontiers in Immunology , 2020 , 11 : 1364 .

LIU M A . Gene-based vaccines: recent developments [J ] . Current Opinion in Molecular Therapeutics , 2010 , 12 ( 1 ): 86 - 93 .

ROBINSON H L , AMARA R R . T cell vaccines for microbial infections [J ] . Nature Medicine , 2005 , 11 ( 4 Suppl ): S25 - S32 .

NIDETZ N F , MCGEE M C , TSE L V , et al . Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery [J ] . Pharmacology & Therapeutics , 2020 , 207 : 107453 .

XU Z L , MIZUGUCHI H , SAKURAI F , et al . Approaches to improving the kinetics of adenovirus-delivered genes and gene products [J ] . Advanced Drug Delivery Reviews , 2005 , 57 ( 5 ): 781 - 802 .

MAYS L E , WILSON J M . The complex and evolving story of T cell activation to AAV vector-encoded transgene products [J ] . Molecular Therapy , 2011 , 19 ( 1 ): 16 - 27 .

HASANPOURGHADI M , NOVIKOV M , ERTL H C J . COVID-19 vaccines based on adenovirus vectors [J ] . Trends in Biochemical Sciences , 2021 , 46 ( 5 ): 429 - 430 .

KOGER-PEASE C , PERERA D J , NDAO M . Recent advances in the development of adenovirus-vectored vaccines for parasitic infections [J ] . Pharmaceuticals , 2023 , 16 ( 3 ): 334 .

LASARO M O , ERTL H C J . New insights on adenovirus as vaccine vectors [J ] . Molecular Therapy , 2009 , 17 ( 8 ): 1333 - 1339 .

ZHOU X Y , XIANG Z Q , ERTL H C J . Vaccine design: replication-defective adenovirus vectors [J ] . Methods in Molecular Biology , 2016 , 1404 : 329 - 349 .

MACNEIL K M , DODGE M J , EVANS A M , et al . Adenoviruses in medicine: innocuous pathogen, predator, or partner [J ] . Trends in Molecular Medicine , 2023 , 29 ( 1 ): 4 - 19 .

TATSIS N , ERTL H C J . Adenoviruses as vaccine vectors [J ] . Molecular Therapy , 2004 , 10 ( 4 ): 616 - 629 .

MIZUGUCHI H , KAY M A , HAYAKAWA T . Approaches for generating recombinant adenovirus vectors [J ] . Advanced Drug Delivery Reviews , 2001 , 52 ( 3 ): 165 - 176 .

KRATZER R F , KREPPEL F . Production, purification, and titration of first-generation adenovirus vectors [J ] . Methods in Molecular Biology , 2017 , 1654 : 377 - 388 .

KAMEN A , HENRY O . Development and optimization of an adenovirus production process [J ] . The Journal of Gene Medicine , 2004 , 6 ( Suppl 1 ): S184 - S192 .

CHAN J F , KOK K H , ZHU Z , et al . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan [J ] . Emerging Microbes & Infections , 2020 , 9 ( 1 ): 221 - 236 .

张倩 , 胡倩倩 , 王富珍 , 等 . 腺病毒载体疫苗研发进展 [J ] . 中国疫苗和免疫 , 2020 , 26 ( 4 ): 484 - 492 .

ZHANG Q , HU Q Q , WANG F Z , et al . Research and development of adenovirus vectored vaccines [J ] . Chinese Journal of Vaccines and Immunization , 2020 , 26 ( 4 ): 484 - 492 .

HALPERIN S A , YE L Y , MACKINNON-CAMERON D , et al . Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial [J ] . Lancet , 2022 , 399 ( 10321 ): 237 - 248 .

PARRINO J , GRAHAM B S . Smallpox vaccines: past, present, and future [J ] . The Journal of Allergy and Clinical Immunology , 2006 , 118 ( 6 ): 1320 - 1326 .

MACKETT M , SMITH G L , MOSS B . Vaccinia virus: a selectable eukaryotic cloning and expression vector [J ] . Proceedings of the National Academy of Sciences of the United States of America , 1982 , 79 ( 23 ): 7415 - 7419 .

PANICALI D , PAOLETTI E . Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus [J ] . Proceedings of the National Academy of Sciences of the United States of America , 1982 , 79 ( 16 ): 4927 - 4931 .

PUISSANT B , COMBADIÈRE B . Keeping the memory of smallpox virus [J ] . Cellular and Molecular Life Sciences , 2006 , 63 ( 19-20 ): 2249 - 2259 .

MOSS B . Vaccinia virus: a tool for research and vaccine development [J ] . Science , 1991 , 252 ( 5013 ): 1662 - 1667 .

NORBURY C C , MALIDE D , GIBBS J S , et al . Visualizing priming of viru s-specific CD8 + T cells by infected dendritic cells in vivo [J ] . Nature Immunology , 2002 , 3 ( 3 ): 265 - 271 .

VAN STIPDONK M J B , HARDENBERG G , BIJKER M S , et al . Dynamic programming of CD8 + T lymphocyte responses [J ] . Nature Immunology , 2003 , 4 ( 4 ): 361 - 365 .

GÓMEZ C E , PERDIGUERO B , GARCIA-ARRIAZA J , et al . Poxvirus vectors as HIV/AIDS vaccines in humans [J ] . Human Vaccines & Immunotherapeutics , 2012 , 8 ( 9 ): 1192 - 1207 .

SÁNCHEZ-SAMPEDRO L , PERDIGUERO B , MEJÍAS-PÉREZ E , et al . The evolution of poxvirus vaccines [J ] . Viruses , 2015 , 7 ( 4 ): 1726 - 1803 .

GUO Z S , LU B F , GUO Z B , et al . Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics [J ] . Journal for Immunotherapy of Cancer , 2019 , 7 ( 1 ): 6 .

SUTTER G , MOSS B . Nonreplicating vaccinia vector efficiently expresses recombinant genes [J ] . Proceedings of the National Academy of Sciences of the United States of America , 1992 , 89 ( 22 ): 10847 - 10851 .

SUTER M , MEISINGER-HENSCHEL C , TZATZARIS M , et al . Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain [J ] . Vaccine , 2009 , 27 ( 52 ): 7442 - 7450 .

VON KREMPELHUBER A , VOLLMAR J , POKORNY R , et al . A randomized, double-blind, dose-finding phase Ⅱ study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE [J ] . Vaccine , 2010 , 28 ( 5 ): 1209 - 1216 .

PITTMAN P R , HAHN M , LEE H S , et al . Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox [J ] . The New England Journal of Medicine , 2019 , 381 ( 20 ): 1897 - 1908 .

MUNIER C M L , ANDERSEN C R , KELLEHER A D . HIV vaccines: progress to date [J ] . Drugs , 2011 , 71 ( 4 ): 387 - 414 .

COTTINGHAM M G , CARROLL M W . Recombinant MVA vaccines: dispelling the myths [J ] . Vaccine , 2013 , 31 ( 39 ): 4247 - 4251 .

ZHOU Y , SULLIVAN N J . Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine [J ] . Current Opinion in Immunology , 2015 , 35 : 131 - 136 .

曾谷城 . 埃博拉病毒研究进展 [J ] . 中山大学学报(医学科学版) , 2015 , 36 ( 2 ): 161 - 166 .

ZENG G C . Progresses and problems in Ebola virus research [J ] . Journal of Sun Yat-Sen University (Medical Sciences) , 2015 , 36 ( 2 ): 161 - 166 .

WU L H , ZHANG Z , GAO H N , et al . Open-label phase Ⅰclinical trial of Ad5-EBOV in Africans in China [J ] . Human Vaccines & Immunotherapeutics , 2017 , 13 ( 9 ): 2078 - 2085 .

MILLIGAN I D , GIBANI M M , SEWELL R , et al . Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial [J ] . JAMA , 2016 , 315 ( 15 ): 1610 - 1623 .

LICHTY B D , POWER A T , STOJDL D F , et al . Vesicular stomatitis virus: re-inventing the bullet [J ] . Trends in Molecular Medicine , 2004 , 10 ( 5 ): 210 - 216 .

FRECHA C , LÉVY C , COSSET F L , et al . Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy [J ] . Molecular Therapy , 2010 , 18 ( 10 ): 1748 - 1757 .

SASSO E , D’ALISE A M , ZAMBRANO N , et al . New viral vectors for infectious diseases and cancer [J ] . Seminars in Immunology , 2020 , 50 : 101430 .

BARBER G N . VSV-tumor selective replication and protein translation [J ] . Oncogene , 2005 , 24 ( 52 ): 7710 - 7719 .

DHAMA K , KARTHIK K , KHANDIA R , et al . Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus [J ] . Frontiers in Immunology , 2018 , 9 : 1803 .

LI H Y , ZHAO C Y , ZHANG Y H , et al . Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays [J ] . Emerging Microbes & Infections , 2020 , 9 ( 1 ): 2269 - 2277 .

SCHNELL M J , BUONOCORE L , KRETZSCHMAR E , et al . Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles [J ] . Proceedings of the National Academy of Sciences of the United States of America , 1996 , 93 ( 21 ): 11359 - 11365 .

CLARKE D K , HENDRY R M , SINGH V , et al . Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk/benefit assessment [J ] . Vaccine , 2016 , 34 ( 51 ): 6597 - 6609 .

GEISBERT T W , FELDMANN H . Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections [J ] . The Journal of Infectious Diseases , 2011 , 204 ( S3 ): S1075 - S1081 .

卢建博 , 郑文铝 , 余云舟 , 等 . 重组水疱性口炎病毒载体病毒包装体系的建立及优化 [J ] . 生物技术通讯 , 2018 , 29 ( 2 ): 183 - 188 .

LU J B , ZHENG W L , YU Y Z , et al . Establishment and optimization of recombinant VSV packaging system [J ] . Letters in Biotechnology , 2018 , 29 ( 2 ): 183 - 188 .

MONATH T P , NICHOLS R , TUSSEY L , et al . Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: model for assessment of live vaccines with neurotropic potential [J ] . PLoS Pathogens , 2022 , 18 ( 6 ): e1010658 .

JOHNSON J E , NASAR F , COLEMAN J W , et al . Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human Primates [J ] . Virology , 2007 , 360 ( 1 ): 36 - 49 .

LAI L L , DAVEY R , BECK A , et al . Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick [J ] . JAMA , 2015 , 313 ( 12 ): 1249 - 1255 .

ROSE N F , MARX P A , LUCKAY A , et al . An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants [J ] . Cell , 2001 , 106 ( 5 ): 539 - 549 .

GIRARD-GAGNEPAIN A , AMIRACHE F , COSTA C , et al . Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs [J ] . Blood , 2014 , 124 ( 8 ): 1221 - 1231 .

FELICIANO D , OTT C M , ESPINOSA-MEDINA I , et al . YAP1 nuclear efflux and transcriptional reprograming follow membrane diminution upon VSV-G-induced cell fusion [J ] . Nature Communications , 2021 , 12 ( 1 ): 4502 .

NIKOLIC J , BELOT L , RAUX H , et al . Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein [J ] . Nature Communications , 2018 , 9 ( 1 ): 1029 .

CASE J B , ROTHLAUF P W , CHEN R E , et al . Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice [J ] . Cell Host & Microbe , 2020 , 28 ( 3 ): 465 - 474.e4 .

SHEN W W , PATNAIK M M , RUIZ A , et al . Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia [J ] . Blood , 2016 , 127 ( 11 ): 1449 - 1458 .

MOROZOV I , MONATH T P , MEEKINS D A , et al . High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission [J ] . Emerging Microbes & Infections , 2021 , 10 ( 1 ): 651 - 663 .

ROEDIGER E K , KUGATHASAN K , ZHANG X Z , et al . Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine [J ] . Molecular Therapy , 2008 , 16 ( 6 ): 1161 - 1169 .

MARZI A , FELDMANN F , GEISBERT T W , et al . Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses [J ] . Emerging Infectious Diseases , 2015 , 21 ( 2 ): 305 - 307 .

IMAZU S , NAKAGAWA S , NAKANISHI T , et al . A novel nonviral vector based on vesicular stomatitis virus [J ] . Journal of Controlled Release , 2000 , 68 ( 2 ): 187 - 194 .

CLARKE D K , COOPER D , EGAN M A , et al . Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector [J ] . Springer Seminars in Immunopathology , 2006 , 28 ( 3 ): 239 - 253 .

WITKO S E , JOHNSON J E , KALYAN N K , et al . Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression [J ] . Journal of Virological Methods , 2010 , 164 ( 1-2 ): 43 - 50 .

FUCHS J , FRANK I , KOCHAR N , et al . First-in-human phase Ⅰ clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine [J ] . Retrovirology , 2012 , 9 ( 2 ): P134 .

FUCHS J D , FRANK I , ELIZAGA M L , et al . First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090) [J ] . Open Forum Infectious Diseases , 2015 , 2 ( 3 ): ofv082 .

WILSON S R , WILSON J H , BUONOCORE L , et al . Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity [J ] . Comparative Medicine , 2008 , 58 ( 2 ): 129 - 139 .

BRANDSMA J L , SHYLANKEVICH M , SU Y H , et al . Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus [J ] . Journal of Virology , 2007 , 81 ( 11 ): 5749 - 5758 .

BRIDLE B W , BOUDREAU J E , LICHTY B D , et al . Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus [J ] . Molecular Therapy , 2009 , 17 ( 10 ): 1814 - 1821 .

HUANG H , WANG Y J , WHITE A P , et al . Salmonella expressing a T-cell epitope from Sendai virus are able to induce anti-infection immunity [J ] . Journal of Medical Microbiology , 2009 , 58 ( Pt 9 ): 1236 - 1242 .

FENNELLY G J , KHAN S A , ABADI M A , et al . Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector [J ] . Journal of Immunology , 1999 , 162 ( 3 ): 1603 - 1610 .

FERRARI G , KOSTYU D D , COX J , et al . Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines [J ] . AIDS Research and Human Retroviruses , 2000 , 16 ( 14 ): 1433 - 1443 .

GAHAN M E , WEBSTER D E , WESSELINGH S L , et al . Bacterial antigen expression is an important component in inducing an immune response to orally administered Salmonella -delivered DNA vaccines [J ] . PLoS One , 2009 , 4 ( 6 ): e6062 .

ZHANG X L , JEZA V T , PAN Q . Salmonella typhi : from a human pathogen to a vaccine vector [J ] . Cellular & Molecular Immunology , 2008 , 5 ( 2 ): 91 - 97 .

MITAMURA T , HIGASHIYAMA S , TANIGUCHI N , et al . Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity [J ] . The Journal of Biological Chemistry , 1995 , 270 ( 3 ): 1015 - 1019 .

BUZZI S , RUBBOLI D , BUZZI G , et al . CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients [J ] . Cancer Immunology, Immunotherapy , 2004 , 53 ( 11 ): 1041 - 1048 .

SHINEFIELD H R . Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use [J ] . Vaccine , 2010 , 28 ( 27 ): 4335 - 4339 .

JIANG S S , NAN F L , ZHANG S Y , et al . CRM197-conjugated multi antigen dominant epitope for effective human cytomegalovirus vaccine development [J ] . International Journal of Biological Macromolecules , 2023 , 224 : 79 - 93 .

ZHANG S Y , NAN F L , JIANG S S , et al . CRM197-conjugated peptides vaccine of HCMV pp65 and gH induce maturation of DC and effective viral-specific T cell responses [J ] . Virulence , 2023 , 14 ( 1 ): 2169488 .

HOEBE K , JANSSEN E , BEUTLER B . The interface between innate and adaptive immunity [J ] . Nature Immunology , 2004 , 5 ( 10 ): 971 - 974 .

SCHOEN C , STRITZKER J , GOEBEL W , et al . Bacteria as DNA vaccine carriers for genetic immunization [J ] . International Journal of Medical Microbiology , 2004 , 294 ( 5 ): 319 - 335 .

DUNHAM S P . The application of nucleic acid vaccines in veterinary medicine [J ] . Research in Veterinary Science , 2002 , 73 ( 1 ): 9 - 16 .

DERTZBAUGH M T . Genetically engineered vaccines: an overview [J ] . Plasmid , 1998 , 39 ( 2 ): 100 - 113 .

MEKONNEN Z A , GRUBOR-BAUK B , MASAVULI M G , et al . Toward DNA-based T-cell mediated vaccines to target HIV-1 and hepatitis C virus: approaches to elicit localized immunity for protection [J ] . Frontiers in Cellular and Infection Microbiology , 2019 , 9 : 91 .

PAGLIARI S , DEMA B , SANCHEZ-MARTINEZ A , et al . DNA vaccines: history, molecular mechanisms and future perspectives [J ] . Journal of Molecular Biology , 2023 , 435 ( 23 ): 168297 .

TIRIVEEDHI V , TUCKER N , HERNDON J , et al . Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer [J ] . Clinical Cancer Research , 2014 , 20 ( 23 ): 5964 - 5975 .

BRENNER S , JACOB F , MESELSON M . An unstable intermediate carrying information from genes to ribosomes for protein synthesis [J ] . Nature , 1961 , 190 : 576 - 581 .

XU S Q , YANG K P , LI R , et al . mRNA vaccine era-mechanisms, drug platform and clinical prospection [J ] . International Journal of Molecular Sciences , 2020 , 21 ( 18 ): 6582 .

WOLFF J A , MALONE R W , WILLIAMS P , et al . Direct gene transfer into mouse muscle in vivo [J ] . Science , 1990 , 247 ( 4949 Pt 1 ): 1465 - 1468 .

SHROFF R T , CHALASANI P , WEI R , et al . Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors [J ] . Nature Medicine , 2021 , 27 ( 11 ): 2002 - 2011 .

JACKSON L A , ANDERSON E J , ROUPHAEL N G , et al . An mRNA vaccine against SARS-CoV-2-preliminary report [J ] . The New England Journal of Medicine , 2020 , 383 ( 20 ): 1920 - 1931 .

HEMMI H , TAKEUCHI O , KAWAI T , et al . A Toll-like receptor recognizes bacterial DNA [J ] . Nature , 2000 , 408 ( 6813 ): 740 - 745 .

KARIKÓ K , BUCKSTEIN M , NI H P , et al . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA [J ] . Immunity , 2005 , 23 ( 2 ): 165 - 175 .

PARDI N , HOGAN M J , PORTER F W , et al . mRNA vaccines - a new era in vaccinology [J ] . Nature Reviews Drug Discovery , 2018 , 17 ( 4 ): 261 - 279 .

FELDMAN R A , FUHR R , SMOLENOV I , et al . mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J ] . Vaccine , 2019 , 37 ( 25 ): 3326 - 3334 .

JONG W , LEAL L , BUYZE J , et al . Therapeutic vaccine in chronically HIV-1-infected patients: a randomized, double-blind, placebo-controlled phase Ⅱa trial with HTI-TriMix [J ] . Vaccines , 2019 , 7 ( 4 ): 209 .

ZHANG N N , LI X F , DENG Y Q , et al . A thermostable mRNA vaccine against COVID-19 [J ] . Cell , 2020 , 182 ( 5 ): 1271 - 1283.e16 .

RICHNER J M , HIMANSU S , DOWD K A , et al . Modified mRNA vaccines protect against Zika virus infection [J ] . Cell , 2017 , 168 ( 6 ): 1114 - 1125.e10 .

XUE T , STAVROPOULOS E , YANG M , et al . RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection [J ] . Infection and Immunity , 2004 , 72 ( 11 ): 6324 - 6329 .

PASTOR F , BERRAONDO P , ETXEBERRIA I , et al . An RNA toolbox for cancer immunotherapy [J ] . Nature Reviews Drug Discovery , 2018 , 17 ( 10 ): 751 - 767 .

TOMBÁCZ I , WEISSMAN D , PARDI N . Vaccination with messenger RNA: a promising alternative to DNA vaccination [J ] . Methods in Molecular Biology , 2021 , 2197 : 13 - 31 .

LINARES-FERNÁNDEZ S , LACROIX C , EXPOSITO J Y , et al . Tailoring mRNA vaccine to balance innate/adaptive immune response [J ] . Trends in Molecular Medicine , 2020 , 26 ( 3 ): 311 - 323 .

FAGHFURI E , POURFARZI F , FAGHFOURI A H , et al . Recent developments of RNA-based vaccines in cancer immunotherapy [J ] . Expert Opinion on Biological Therapy , 2021 , 21 ( 2 ): 201 - 218 .

VAN NUFFEL A M , WILGENHOF S , THIELEMANS K , et al . Overcoming HLA restriction in clinical trials: immune monitoring of mRNA-loaded DC therapy [J ] . Oncoimmunology , 2012 , 1 ( 8 ): 1392 - 1394 .

IAVARONE C , O’HAGAN D T , YU D , et al . Mechanism of action of mRNA-based vaccines [J ] . Expert Review of Vaccines , 2017 , 16 ( 9 ): 871 - 881 .

SAXENA M , VAN DER BURG S H , MELIEF C J M , et al . Therapeutic cancer vaccines [J ] . Nature Reviews Cancer , 2021 , 21 ( 6 ): 360 - 378 .

JIANG T , ZHOU C C , REN S X . Role of IL-2 in cancer immunotherapy [J ] . Oncoimmunology , 2016 , 5 ( 6 ): e1163462 .

BECK J D , REIDENBACH D , SALOMON N , et al . mRNA therapeutics in cancer immunotherapy [J ] . Molecular Cancer , 2021 , 20 ( 1 ): 69 .

SAHIN U , MUIK A , DERHOVANESSIAN E , et al . COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses [J ] . Nature , 2020 , 586 ( 7830 ): 594 - 599 .

KRAMMER F . SARS-CoV-2 vaccines in development [J ] . Nature , 2020 , 586 ( 7830 ): 516 - 527 .

EBERHARDT C S , SIEGRIST C A . Is there a role for childhood vaccination against COVID-19? [J ] . Pediatric Allergy and Immunology , 2021 , 32 ( 1 ): 9 - 16 .

袁军鸿 , 杨昭庆 , 马绍辉 . mRNA疫苗的研究进展 [J ] . 中国生物制品学杂志 , 2022 ( 6 ): 734 - 739 .

YUAN J H , YANG Z Q , MA S H . Progress in research on mRNA vaccines [J ] . Chinese Journal of Biologicals , 2022 ( 6 ): 734 - 739 .

胡佳欣 , 章晓联 . mRNA疫苗的原理、研究现状和展望 [J ] . 武汉大学学报(医学版) , 2023 , 44 ( 9 ): 1033 - 1045 .

HU J X , ZHANG X L . mRNA vaccines: principle, current status and perspectives [J ] . Medical Journal of Wuhan University , 2023 , 44 ( 9 ): 1033 - 1045 .

SELBY L I , CORTEZ-JUGO C M , SUCH G K , et al . Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles [J ] . Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology , 2017 , 9 ( 5 ): e1452 .

CAGIGI A , LORÉ K . Immune responses induced by mRNA vaccination in mice, monkeys and humans [J ] . Vaccines , 2021 , 9 ( 1 ): 61 .

NATAMI M , GORGZADEH A , GHOLIPOUR A , et al . An overview on mRNA-based vaccines to prevent monkeypox infection [J ] . Journal of Nanobiotechnology , 2024 , 22 ( 1 ): 86 .

HOU F J , ZHANG Y T , LIU X H , et al . mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge [J ] . Nature Communications , 2023 , 14 ( 1 ): 5925 .

WANG H , YIN P , ZHENG T T , et al . Rational design of a ‘two-in-one’ immunogen DAM drives potent immune response against mpox virus [J ] . Nature Immunology , 2024 , 25 ( 2 ): 307 - 315 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Dawn of the rational design of nanoparticle vaccines aided by the advance of synthetic biology techniques

Current developments in the use of engineered bacteria for cancer therapy

Progress of bispecific antibodies and nanotechnology in tumor immunotherapies

Related Author

HOU Baidong

HUA Zhaolin

GUO Chang

MA Xuejing

SUN Haitao

HUANG Jiandong

CHEN Jiawen

XU Haiyan

Related Institution

Changping Laboratory

University of Chinese Academy of Sciences

CAS Key Laboratory of Infection and Immunity， Institute of Biophysics， Chinese Academy of Sciences

School of Biomedical Sciences， Li Ka Shing Faculty of Medicine， The University of Hong Kong

Hong Kong Joint Laboratory for RNA Medicine， Sun Yat-Sen University

⁰